Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Short Interest Down 37.2% in May

Cosmo Pharmaceuticals (OTCMKTS:CMOPF) was the target of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 14,592 shares, a decrease of 37.2% from the April 30th total of 23,228 shares. Based on an average daily volume of 597 shares, the days-to-cover ratio is presently 24.4 days.

Cosmo Pharmaceuticals Stock Performance

Shares of CMOPF opened at C$92.60 on Wednesday. Cosmo Pharmaceuticals has a fifty-two week low of C$75.00 and a fifty-two week high of C$169.90. The firm’s 50-day simple moving average is C$106.66 and its two-hundred day simple moving average is C$120.54.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.